PRF Technologies (PRFX) Other financing activities (2021 - 2025)

PRF Technologies' (PRFX) quarterly Other financing activities came in at $8400.0 in Q4 2025, down 99.73% on a QoQ basis from $3.1 million in Q4 2023.

PRF Technologies (PRFX) Other financing activities (2021 - 2025) Analysis & Trends

PRF Technologies (PRFX) has 3 years of Other financing activities data on file, last reported at $8400.0 in Q4 2025.

Quarterly Other financing activities changed N/A year-over-year to $8400.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $219400.0 (changed N/A YoY) and the FY2025 annual result came in at $190000.0, down 94.0% from the prior year.
Other financing activities slipped to $8400.0 in Q4 2025, from $3.1 million in the prior quarter.
In the past five years, Other financing activities ranged from a high of $3.1 million in Q4 2023 to a low of -$2.3 million in Q2 2023.
A 3-year average of $358233.3 and a median of -$218800.0 in 2021 frame the typical range for Other financing activities.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	44.43 Bn	43.46 Bn	-
2	Teva Pharmaceutical Industries	43.72 Bn	40.07 Bn	2.15 Bn
3	Zoetis	32.38 Bn	30.70 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn
5	United Therapeutics	22.13 Bn	19.46 Bn	683.80 Mn
6	Viatris	18.87 Bn	17.99 Bn	1.46 Bn
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn
8	Elanco Animal Health	11.99 Bn	11.46 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-
10	PRF Technologies	645,251.53	-3.50 Mn	-

Download Data